미생물 발효 CMO 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently published a comprehensive report detailing the global microbial fermentation contract manufacturing organization (CMO) market. The report offers a thorough assessment of key market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global microbial fermentation CMO market from 2024 to 2031.

Key Insights:

• Microbial Fermentation CMO Market Size (2024E): US$3.8 Bn
• Projected Market Value (2031F): US$6.9 Bn
• Forecast Growth Rate (CAGR 2024-2031): 8.9%

Microbial Fermentation CMO Market - Report Scope:

The microbial fermentation CMO market plays a critical role across various sectors, including pharmaceuticals, food and beverages, agriculture, and industrial manufacturing. This market leverages microorganisms like bacteria, yeast, and fungi to produce valuable products. As demand for biopharmaceuticals surges, driven by the need for antibiotics, vaccines, and enzymes, pharmaceutical companies increasingly rely on CMOs for production and scale-up.

Market Growth Drivers:

The global microbial fermentation CMO market is propelled by several key factors, including the increasing prevalence of chronic diseases and the urgent need for advanced therapeutic solutions. As the demand for biopharmaceuticals continues to rise, driven by conditions such as diabetes, cancer, and autoimmune disorders, the necessity for advanced therapeutic solutions intensifies. This shift emphasizes the importance of flexible and scalable fermentation processes that CMOs specialize in.

Market Restraints:

Despite the positive growth outlook, the microbial fermentation CMO market faces challenges related to supply chain complexities. Issues in sourcing high-quality raw materials and logistical challenges in transporting sensitive biological materials significantly hinder market efficiency. Inconsistent availability and quality of essential substrates for fermentation processes can lead to production delays and increased costs, impacting the ability of CMOs to meet rising demand.

Market Opportunities:

The microbial fermentation CMO market presents significant growth opportunities driven by sustainability and green technologies. Companies are increasingly adopting sustainable practices to reduce their environmental impact, including optimizing fermentation processes to minimize waste and energy consumption. This aligns with the global sustainability movement, presenting a massive market opportunity for CMOs that prioritize environmentally friendly practices.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the microbial fermentation CMO market globally?
• How are advancements in biotechnology reshaping the competitive landscape of the microbial fermentation CMO market?
• What regulatory challenges are impacting the operations of CMOs in the biopharmaceutical sector?
• Which companies are the key players in the microbial fermentation CMO market, and what strategies are they employing to maintain relevance?
• What emerging trends and future prospects are anticipated in the global microbial fermentation CMO market?

Competitive Intelligence and Business Strategy:

Leading players in the global microbial fermentation CMO market, including Lonza, Samsung Biologics, and WuXi Biologics, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies are investing heavily in R&D to develop advanced fermentation technologies and scalable manufacturing solutions catering to diverse therapeutic needs. Collaborations with regulatory agencies, research institutions, and healthcare providers facilitate market access and promote technology adoption.

Key Companies Profiled:

• AbbVie Inc.
• BOC Sciences
• Eurofins Scientific
• FUJIFILM Diosynth Biotechnologies
• GSK plc
• Lonza Group AG
• Sandoz Group AG
• WuXi Biologics
• Evonik Industries
• DSM
• Sekisui Diagnostics
• AGC Biologics
• BIOVECTRA
• Avid Bioservices

Microbial Fermentation CMO Market Segmentation

By Expression System

• Bacterial Expression Systems
• Yeast Expression Systems
• Others

By Biologics

• Enzymes
• Antibodies
• Plasmid DNA
• Recombinant Proteins
• Others

By End User

• Biopharma Companies
• Academic & Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• The Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Microbial Fermentation CMO Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Value Chain Analysis
• 3.3. Key Deals and Mergers
• 3.4. PESTLE Analysis
• 3.5. Porter's Five Force Analysis

4. Global Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Microbial Fermentation CMO Market Outlook: Type of Expression Systems
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Type of Expression Systems, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
    • 4.3.3.1. Bacterial Expression Systems
    • 4.3.3.2. Yeast Expression Systems
    • 4.3.3.3. Others
• 4.4. Market Attractiveness Analysis: Type of Expression Systems
• 4.5. Global Microbial Fermentation CMO Market Outlook: Type of Biologics
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Type of Biologics, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
    • 4.5.3.1. Enzymes
    • 4.5.3.2. Antibodies
    • 4.5.3.3. Plasmid DNA
    • 4.5.3.4. Recombinant Proteins
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Type of Biologics
• 4.7. Global Microbial Fermentation CMO Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
    • 4.7.3.1. Biopharma Companies
    • 4.7.3.2. Academic & Research Institutes
    • 4.7.3.3. Others
• 4.8. Market Attractiveness Analysis: End User

5. Global Microbial Fermentation CMO Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Type of Expression Systems
  • 6.2.3. By Type of Biologics
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 6.4.1. Bacterial Expression Systems
  • 6.4.2. Yeast Expression Systems
  • 6.4.3. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 6.5.1. Enzymes
  • 6.5.2. Antibodies
  • 6.5.3. Plasmid DNA
  • 6.5.4. Recombinant Proteins
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 6.6.1. Biopharma Companies
  • 6.6.2. Academic & Research Institutes
  • 6.6.3. Others
• 6.7. Market Attractiveness Analysis

7. Europe Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Type of Expression Systems
  • 7.2.3. By Type of Biologics
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 7.4.1. Bacterial Expression Systems
  • 7.4.2. Yeast Expression Systems
  • 7.4.3. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 7.5.1. Enzymes
  • 7.5.2. Antibodies
  • 7.5.3. Plasmid DNA
  • 7.5.4. Recombinant Proteins
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 7.6.1. Biopharma Companies
  • 7.6.2. Academic & Research Institutes
  • 7.6.3. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Type of Expression Systems
  • 8.2.3. By Type of Biologics
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 8.4.1. Bacterial Expression Systems
  • 8.4.2. Yeast Expression Systems
  • 8.4.3. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 8.5.1. Enzymes
  • 8.5.2. Antibodies
  • 8.5.3. Plasmid DNA
  • 8.5.4. Recombinant Proteins
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 8.6.1. Biopharma Companies
  • 8.6.2. Academic & Research Institutes
  • 8.6.3. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Type of Expression Systems
  • 9.2.3. By Type of Biologics
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 9.4.1. Bacterial Expression Systems
  • 9.4.2. Yeast Expression Systems
  • 9.4.3. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 9.5.1. Enzymes
  • 9.5.2. Antibodies
  • 9.5.3. Plasmid DNA
  • 9.5.4. Recombinant Proteins
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 9.6.1. Biopharma Companies
  • 9.6.2. Academic & Research Institutes
  • 9.6.3. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Type of Expression Systems
  • 10.2.3. By Type of Biologics
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 10.4.1. Bacterial Expression Systems
  • 10.4.2. Yeast Expression Systems
  • 10.4.3. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 10.5.1. Enzymes
  • 10.5.2. Antibodies
  • 10.5.3. Plasmid DNA
  • 10.5.4. Recombinant Proteins
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 10.6.1. Biopharma Companies
  • 10.6.2. Academic & Research Institutes
  • 10.6.3. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Type of Expression Systems
  • 11.2.3. By Type of Biologics
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
  • 11.4.1. Bacterial Expression Systems
  • 11.4.2. Yeast Expression Systems
  • 11.4.3. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
  • 11.5.1. Enzymes
  • 11.5.2. Antibodies
  • 11.5.3. Plasmid DNA
  • 11.5.4. Recombinant Proteins
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 11.6.1. Biopharma Companies
  • 11.6.2. Academic & Research Institutes
  • 11.6.3. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Structure
  • 12.1.1. Competition Intensity Mapping By Market
  • 12.1.2. Competition Dashboard
• 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.2.1. AbbVie Inc.
    • 12.2.1.1. Overview
    • 12.2.1.2. Segments and Products
    • 12.2.1.3. Key Financials
    • 12.2.1.4. Market Developments
    • 12.2.1.5. Market Strategy
  • 12.2.2. BOC Sciences
    • 12.2.2.1. Overview
    • 12.2.2.2. Segments and Products
    • 12.2.2.3. Key Financials
    • 12.2.2.4. Market Developments
    • 12.2.2.5. Market Strategy
  • 12.2.3. Eurofins Scientific
    • 12.2.3.1. Overview
    • 12.2.3.2. Segments and Products
    • 12.2.3.3. Key Financials
    • 12.2.3.4. Market Developments
    • 12.2.3.5. Market Strategy
  • 12.2.4. FUJIFILM Diosynth Biotechnologies
    • 12.2.4.1. Overview
    • 12.2.4.2. Segments and Products
    • 12.2.4.3. Key Financials
    • 12.2.4.4. Market Developments
    • 12.2.4.5. Market Strategy
  • 12.2.5. GSK plc
    • 12.2.5.1. Overview
    • 12.2.5.2. Segments and Products
    • 12.2.5.3. Key Financials
    • 12.2.5.4. Market Developments
    • 12.2.5.5. Market Strategy
  • 12.2.6. Lonza Group AG
    • 12.2.6.1. Overview
    • 12.2.6.2. Segments and Products
    • 12.2.6.3. Key Financials
    • 12.2.6.4. Market Developments
    • 12.2.6.5. Market Strategy
  • 12.2.7. Sandoz Group AG
    • 12.2.7.1. Overview
    • 12.2.7.2. Segments and Products
    • 12.2.7.3. Key Financials
    • 12.2.7.4. Market Developments
    • 12.2.7.5. Market Strategy
  • 12.2.8. WuXi Biologics
    • 12.2.8.1. Overview
    • 12.2.8.2. Segments and Products
    • 12.2.8.3. Key Financials
    • 12.2.8.4. Market Developments
    • 12.2.8.5. Market Strategy
  • 12.2.9. Evonik Industries
    • 12.2.9.1. Overview
    • 12.2.9.2. Segments and Products
    • 12.2.9.3. Key Financials
    • 12.2.9.4. Market Developments
    • 12.2.9.5. Market Strategy
  • 12.2.10. DSM
    • 12.2.10.1. Overview
    • 12.2.10.2. Segments and Products
    • 12.2.10.3. Key Financials
    • 12.2.10.4. Market Developments
    • 12.2.10.5. Market Strategy
  • 12.2.11. Sekisui Diagnostics
    • 12.2.11.1. Overview
    • 12.2.11.2. Segments and Products
    • 12.2.11.3. Key Financials
    • 12.2.11.4. Market Developments
    • 12.2.11.5. Market Strategy
  • 12.2.12. AGC Biologics
    • 12.2.12.1. Overview
    • 12.2.12.2. Segments and Products
    • 12.2.12.3. Key Financials
    • 12.2.12.4. Market Developments
    • 12.2.12.5. Market Strategy
  • 12.2.13. BIOVECTRA
    • 12.2.13.1. Overview
    • 12.2.13.2. Segments and Products
    • 12.2.13.3. Key Financials
    • 12.2.13.4. Market Developments
    • 12.2.13.5. Market Strategy
  • 12.2.14. Avid Bioservices
    • 12.2.14.1. Overview
    • 12.2.14.2. Segments and Products
    • 12.2.14.3. Key Financials
    • 12.2.14.4. Market Developments
    • 12.2.14.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations